Abstract
The modified vaccinia virus Ankara (MVA) strain, which has been developed as a vaccine against smallpox, is since the nineties widely tested in clinical trials as recombinant vector for vaccination or gene therapy applications. Although MVA is renowned for its safety, several biosafety aspects need to be considered when performing the risk assessment of a recombinant MVA (rMVA). This paper presents the biosafety issues and the main lessons learned from the evaluation of the clinical trials with rMVA performed in Belgium. Factors such as the specific characteristics of the rMVA, the inserted foreign sequences/transgene, its ability for reconversion, recombination and dissemination in the population and the environment are the main points of attention. Measures to prevent or manage identified risks are also discussed.
Keywords: Biosafety, clinical trials, environmental risk assessment, gene therapy, GMO-based vaccines, MVA-based recombinant vectors.
Current Gene Therapy
Title:Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors
Volume: 13 Issue: 6
Author(s): Martine Goossens, Katia Pauwels, Nicolas Willemarck and Didier Breyer
Affiliation:
Keywords: Biosafety, clinical trials, environmental risk assessment, gene therapy, GMO-based vaccines, MVA-based recombinant vectors.
Abstract: The modified vaccinia virus Ankara (MVA) strain, which has been developed as a vaccine against smallpox, is since the nineties widely tested in clinical trials as recombinant vector for vaccination or gene therapy applications. Although MVA is renowned for its safety, several biosafety aspects need to be considered when performing the risk assessment of a recombinant MVA (rMVA). This paper presents the biosafety issues and the main lessons learned from the evaluation of the clinical trials with rMVA performed in Belgium. Factors such as the specific characteristics of the rMVA, the inserted foreign sequences/transgene, its ability for reconversion, recombination and dissemination in the population and the environment are the main points of attention. Measures to prevent or manage identified risks are also discussed.
Export Options
About this article
Cite this article as:
Goossens Martine, Pauwels Katia, Willemarck Nicolas and Breyer Didier, Environmental Risk Assessment of Clinical Trials Involving Modified Vaccinia Virus Ankara (MVA)-Based Vectors, Current Gene Therapy 2013; 13 (6) . https://dx.doi.org/10.2174/156652321306140103221941
DOI https://dx.doi.org/10.2174/156652321306140103221941 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Review of the Essential Oil Composition of Iranian Endemic and Native Taxa of Apiaceae (Umbelliferae)
Current Organic Chemistry From Cocaine to Ropivacaine: The History of Local Anesthetic Drugs
Current Topics in Medicinal Chemistry Expression and Functions of Heat Shock Proteins in the Normal and Pathological Mammalian Eye
Current Molecular Medicine Molecular Fundamentals and Rationale for Immunotherapy in Metastatic Melanoma Treatment
Clinical Cancer Drugs An Uncommon Case of Symptomatic Multiple Meningiomas with Bilateral Compressive Optic Neuropathy Rapidly Induced under Cyprotero ne Acetate Treatment
Current Drug Safety Alkynes as Privileged Synthons in Selected Organic Name Reactions
Current Organic Synthesis The Role of ROS and RNS in Regulating Life and Death of Blood Monocytes
Current Pharmaceutical Design Electrochemical Behaviors and Determinations of Some 2,5-Disubstituted Benzoxazole Compounds at the Hanging Mercury Drop Electrode
Current Pharmaceutical Analysis Current Biology of MTP: Implications for Selective Inhibition
Current Topics in Medicinal Chemistry In Utero Gene Therapy: Prospect and Future
Current Pharmaceutical Design One Decade Later: What has Gene Expression Profiling Told us About Neuronal Cell Types, Brain Function and Disease?
Current Genomics Glaucoma Eye Drops Adverse Skin Reactions
Recent Patents on Inflammation & Allergy Drug Discovery From the Obscure and Mysterious Acute Phase Response to Toll-Like Receptors and the Cytokine Network
Current Immunology Reviews (Discontinued) Treatment of Psoriasis: A Comprehensive Review of Entire Therapies
Current Drug Safety Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design Fluorescent Probes for Detection of Lead Ion
Recent Innovations in Chemical Engineering Interactions of the Aryl Hydrocarbon Receptor with Inflammatory Mediators:Beyond CYP1A Regulation
Current Drug Metabolism Strategy for a Genetic Assessment of Antipsychotic and Antidepressant- Related Proarrhythmia
Current Medicinal Chemistry Curcumin and its Multi-target Function Against Pain and Inflammation: An Update of Pre-clinical Data
Current Drug Targets An Overview on Keratinocyte Growth Factor: From the Molecular Properties to Clinical Applications
Protein & Peptide Letters